430 related articles for article (PubMed ID: 32771986)
1. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
Beavis AL; Yen TT; Stone RL; Wethington SL; Carr C; Son J; Chambers L; Michener CM; Ricci S; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan AN; Jager LR; Fader AN
Gynecol Oncol; 2020 Mar; 156(3):568-574. PubMed ID: 31948730
[TBL] [Abstract][Full Text] [Related]
3. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
[TBL] [Abstract][Full Text] [Related]
5. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
6. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
[TBL] [Abstract][Full Text] [Related]
7. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
8. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Backes FJ; Felix AS; Plante M; Grégoire J; Sullivan SA; Rossi EC; Tanner EJ; Stewart KI; Soliman PT; Holloway RW; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 May; 161(2):347-352. PubMed ID: 33678480
[TBL] [Abstract][Full Text] [Related]
10. Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy.
Reshko LB; Gaskins JT; Dryden SM; Metzinger DS; Todd SL; Eldredge-Hindy HB; Silva SR
Int J Gynecol Cancer; 2021 May; 31(5):694-701. PubMed ID: 33741653
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
13. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.
Montes de Oca MK; Albright BB; Secord AA; Havrilesky LJ; Moss HA
Int J Gynecol Cancer; 2021 Dec; 31(12):1549-1556. PubMed ID: 34725205
[TBL] [Abstract][Full Text] [Related]
15. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
16. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
17. Isolated tumor cells identified by sentinel lymph node mapping in endometrial cancer: Does adjuvant treatment matter?
Plante M; Stanleigh J; Renaud MC; Sebastianelli A; Grondin K; Grégoire J
Gynecol Oncol; 2017 Aug; 146(2):240-246. PubMed ID: 28577885
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of recurrence in early-stage endometrial carcinoma after delays in adjuvant radiation treatment.
Zhu S; Khalil R; Altairy O; Burmeister C; Dimitrova I; Elshaikh M
Int J Gynecol Cancer; 2021 Jan; 31(1):73-77. PubMed ID: 33087415
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma.
Yoon MS; Huh SJ; Kim HJ; Kim YS; Kim YB; Kim JY; Lee JH; Kim HJ; Cha J; Kim JH; Kim J; Yoon WS; Choi JH; Chun M; Choi Y; Lee KK; Kim M; Jeong JU; Chang SK; Park W
Cancer Res Treat; 2016 Jul; 48(3):1074-83. PubMed ID: 26511800
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy in stage III endometrial cancer: treatment outcomes and survival. a single-institution retrospective study.
Kuku S; Williams M; McCormack M
Int J Gynecol Cancer; 2013 Jul; 23(6):1056-64. PubMed ID: 23765205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
